Latin America Rhinoconjunctivitis Market

Latin America Rhinoconjunctivitis Market Size & Growth (2022 to 2027):

The Size of the Rhinoconjunctivitis Market in Latin America is valued at USD xx Million in 2022 and is projected to reach USD xx Million by 2027, to grow at a CAGR of xx.x% during the forecast period 2022 to 2027.

Increased awareness in major developing countries and the incidence of rhinoconjunctivitis will be a critical factor in market growth during the study period. A recently published Journal of Allergy and Therapy mentions that allergic rhinoconjunctivitis is the most prevalent reason for hospital visits due to allergies. Others also report that most asthma patients also suffer from this condition, and more than 22% of rhino conjunctivitis patients also have concomitant asthma. The prevalence of allergic rhinitis has increased dramatically in adults and children.  More than 62% of children suffering from rhinoconjunctivitis also had eye symptoms, often poorly recognized as allergic, by 20.

An article published in the World Allergy Organizations Journal suggests no specific data available to study the prevalence and changing trends for this disorder. Therefore, it has hampered research and development activities. According to the same study, most non-food allergies have also been increasing rapidly. In a report published by the Health Authority, a considerable increase in the prevalence of rhinoconjunctivitis has been observed changing seasons.  Ongoing research and development and increasing awareness of allergies would also support growth, especially in developing countries. According to a recently published study in Allergy, Asthma & Immunology Research Journal, consuming foods stored mainly in refrigerators, industrialization, and air pollution are responsible for increasing incidence.

Some certain restrictions and barriers will limit the growth of this market. For example, the expiration of patents, reduced efficacy in some patients, and competition from generic drugs coupled with growing preference for complementary and alternative therapies are potential restraints hampering the overall growth.

This research report on the Latin America Rhinoconjunctivitis Market has been segmented and sub-segmented into the following categories

By Treatment:

• Decongestants
• Mast-Cell Stabilizers
• Antihistamines
• Nonsteroidal Anti-Inflammatory Drugs
• Intranasal Corticosteroids

By Country:

• Mexico
• Brazil
• Argentina
• Chile
• the Rest of Latin America

Geographically, the Argentina rhinoconjunctivitis market dominated the Latin America rhinoconjunctivitis market due to the large population and increased number of conjunctivitis cases. As per the recent study, rhinitis-related symptoms were higher among the Spanish-speaking countries in Latin America. The majority of rhinoconjunctivitis in the past year has been seen from 0.81% to 14.92% in the 6-7-year-olds and 1.45% to 39.72% in the 13-14-year-olds children. This region will continue to dominate during the forecast period, owing to the growing awareness, supportive initiatives, expansion of healthcare infrastructure, and the growth of the R&D sector.

The growing availability of healthcare facilities for people all over Latin America to allergic reactions is the primary factor predicted to drive the growth of the Latin America rhinoconjunctivitis market. In addition, the availability of various modes of drug delivery and better quality of drugs and nasal sprays made by manufacturers for effective treatment is expected to boost the market in the year to come. Furthermore, poor sanitary habits, overexposure to allergic substances, and heavy tobacco consumption will increase prevalence. These factors have positively anticipated the growth of markets in Peru, Puerto Rico, Ecuador, and Chile.

KEY MARKET PLAYERS

Noteworthy Companies dominating the Latin America Rhinoconjunctivitis Market Profiled in the Report are Johnson & Johnson Inc., Merck & Co., Inc., GlaxoSmithKline, Sanofi Adiga Life Sciences Inc.,